Articles by Damion Nero, PhD
Real-World Outcomes Among Patients With Early Rapidly Progressive Rheumatoid Arthritis
ByAndrew J. Klink, PhD, MPH,Tammy G. Curtice, PharmD, MBA, MS,Kiran Gupta, PhD, MPharm,Kenneth W. Tuell, RPh, BCGP,A. Richard Szymialis, RPh,Damion Nero, PhD,Bruce A. Feinberg, DO This study suggests that lower healthcare resource use and achieving low disease activity are associated with first-line abatacept compared with a first-line tumor necrosis factor-α inhibitor for patients with early rapidly progressive rheumatoid arthritis.
Relationship of Diabetes Complications Severity to Healthcare Utilization and Costs Among Medicare Advantage Beneficiaries
ByLeslie Hazel-Fernandez, PhD, MPH,Yong Li, PhD,Damion Nero, PhD,Chad Moretz, ScD,S. Lane Slabaugh, PharmD, MBA,Yunus Meah, PharmD,Jean Baltz, MMSc, MSW,Nick C. Patel, PharmD, PhD,Jonathan R. Bouchard, MS, RPh This retrospective cohort study in a Medicare Advantage population posits that type 2 diabetes mellitus complications pose an excess burden on healthcare resource use and related costs.
